Zero Tolerance Under Prohibition: Argentina and the Adaptation of Criminal Networks

Key Takeaways

• Zero Tolerance intensifies militarized enforcement while preserving illicit market rents
• Hospital drug diversion reveals cracks in pharmaceutical traceability
• Violence shifts from Rosario to Greater Buenos Aires peripheries
• Criminal groups adopt corporate‑like, decentralized structures
• Prohibition fuels illicit capital infiltration into political financing

Pulse Analysis

Argentina’s Zero Tolerance agenda, unveiled by President Javier Milei, marks a decisive shift toward harsher law‑enforcement tools, expanded surveillance, and deeper cooperation with U.S. counternarcotics agencies. While the rhetoric frames the policy as a libertarian crusade against crime, the reality is a paradoxical expansion of state power—greater police authority, longer sentences, and intensified border controls. This contradiction erodes public trust and fuels a narrative that the state is both the problem and the solution, complicating any move toward evidence‑based drug reform seen in neighboring Uruguay and Portugal.

The enforcement surge has not dismantled supply chains; instead, it has accelerated their evolution. Hospital‑linked fentanyl and propofol leaks illustrate how strict prohibition creates lucrative diversion opportunities within highly regulated environments, prompting criminal actors to infiltrate health‑care logistics. Simultaneously, homicide rates have fallen in Rosario under Plan Bandera, yet violence has migrated to the periphery of Greater Buenos Aires, where fragmented gangs vie for territory. These groups now resemble corporate entities—operating through subcontracting, franchising, and diversified illegal portfolios—making them harder to target with traditional, hierarchy‑focused policing.

For policymakers, the lesson is clear: punitive, Zero Tolerance tactics generate short‑term metrics but fail to address the underlying rent‑seeking dynamics that sustain illicit markets. A shift toward harm‑reduction, robust pharmaceutical oversight, and financial transparency could curb the flow of illicit capital into political financing, a risk highlighted by recent allegations linking drug traffickers to campaign donors. Aligning security strategy with public‑health principles and regional best practices would reduce market scarcity, diminish criminal incentives, and ultimately restore state legitimacy without expanding coercive power.